Workshop on Intratumoral Immunomodulation • Nov. 7, 2019

Thursday, Nov. 7, 2019
8 a.m. 5 p.m.

Program Purpose

Immunotherapy treatments inherently rely on the presence of immune cells, both systemic and localized to the tumor microenvironment. Immunologically “hot” tumors, such as melanoma, have demonstrated enhanced responses to immunotherapy treatments; however, many tumors are “cold”, lacking the necessary immune components for a successful treatment. Many techniques, including radiotherapy, synthetic immunomodulators, oncolytic viruses, and certain systemic treatments, have been shown to manipulate the immune status of the treated tumor microenvironment, and even those tumor sites elsewhere in the body (abscopal effects). Such manipulations can increase the presence of desirable immune infiltrates and potentially lead to favorable treatment outcomes. In this workshop, the current status of intratumoral immunomodulation will be presented and future directions for the field will be discussed, along with their implications for current and forthcoming immunotherapy treatments.

Intended Audience

The intended audience for this program includes: basic scientists and clinical investigators from academic institutions, venture capital, industry, and regulatory agencies. Additional audiences benefiting from this program include clinicians, graduate students, and postdoctoral fellows involved in cancer research and its translation into clinical practice.

Workshop Organizers

  • Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai
  • Adi Diab, MD – The University of Texas MD Anderson Cancer Center

Educational Objectives

Upon Completion of this meeting, participants will be able to:

  • Describe the importance of the intratumoral immune environment and its implications for cancer treatment outcomes
  • Discuss the role and mechanisms of radiation treatments in intratumoral immunomodulation
  • Understand the effects of intratumoral synthetic immunomodulators and oncolytic viral therapies on the tumor microenvironment
  • Explain the impact that systemic combination treatments may have on local intratumoral immunomodulation as well as the impact localized treatment can have on the immune status of the rest of the body

SITC's Workshop on Intratumoral Immunomodulation is supported in part by grants from Idera Pharmaceuticals and Pfizer, Inc. (as of June 19, 2019)

Program Schedule

Thursday, Nov. 7, 2019
8 a.m. Introduction

Session 1: Introduction to Intratumoral Immunomodulation
Time:

8:05 9:05 a.m.

8:05 a.m.

Background and Introduction to Intratumoral Therapy
Aurélien Marabelle, MD, PhD – Gustave Roussy

8:25 a.m.

Cold vs. Hot Tumors
Razvan Cristescu, PhD - Merck

8:45 a.m.

Target Cells
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai

Session 2: Modes of Delivery
Time:

9:05 10:25 a.m.

9:05 a.m.

Introduction to Intratumoral Therapy
Aurélien Marabelle, MD, PhD – Gustave Roussy

9:20 a.m.

Modes of Intratumoral Injections: Complexities and Approaches
Rahul Sheth, MD – The University of Texas MD Anderson Cancer Center

9:45 a.m.

Role of Radiation in STING Activation
Sandra Demaria, MD – Weill Cornell Medicine

10:05 a.m.

SBRT and Immune Activation
Silvia Formenti, MD – New York-Presbyterian/Weill Cornell Medical Center

10:25 a.m.

Break

Session 3: Intratumoral Synthetic Modulators
Time

10:40 a.m. 12 p.m.

10:40 a.m.

TLR3
Joshua Brody, MD – Icahn School of Medicine at Mount Sinai

11 a.m.

TLR9
Adi Diab, MD – University of Texas MD Anderson Cancer Center

11:20 a.m

TLR7/8
Willem W. Overwijk, PhD – Nektar Therapeutics

11:40 a.m.

STING Pathways
Thomas W. Dubensky, PhD – Tempest Therapeutics

12 p.m.

Lunch

Session 4: Intratumoral Oncolytic Modulators
Time:

1 2 p.m.

1 p.m.

T-VEC
Howard L. Kaufman, MD, FACS – Replimune Group Inc.

1:20 p.m.

Newcastle Disease Virus Therapy in Cancer
Dmitry Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

1:40 p.m.

Oncolytic Viruses
John Bell, PhD – University of Ottawa

Session 5: Systemic Combinations

Time:

2 4:55 p.m.

2 p.m.

Intratumoral Checkpoint Blockade Inhibition
Craig L. Slingluff, MD – University of Virginia

2:20 p.m.

Anti-Tumor Vaccines Platforms
Esteban Celis, MD, PhD – Augusta University

2:40 p.m.

Break

3 p.m.

CD40: A Target for Systemic Immune Modulation
Michael Yellin, MD – Celldex Therapeutics, Inc.

3:20 p.m.

Clinical Assessment of Intratumoral Immunomodulation
Jianda Yuan, MD, PhD – Merck Research Laboratories

3:40 p.m.

Regulatory Implications for Drug Development
Maitreyee Hazarika, MD – U.S Food and Drug Administration

4 p.m.

Systemic Combinations Panel Discussion
Moderators: Adi Diab, MD – University of Texas MD Anderson Cancer Center
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai

Panelists:
Esteban Celis, MD, PhD – Augusta University
Maitreyee Hazarika, MD – U.S Food and Drug Administration
Jason Luke, MD, FACP – UPMC
Craig L. Slingluff, MD – University of Virginia
Michael Yellin, MD – Celldex Therapeutics, Inc.
Jianda Yuan, MD, PhD – Merck Research Laboratories

4:55 p.m.

Closing

5 p.m.

Adjourn

​​​​​​​​​​​

Schedule At-a-Glance

Wednesday, Nov. 6
World Immunotherapy Council's 3rd Young Investigator Symposium  
Novel Multi-Targeted Therapeutic Platforms
Thursday, Nov. 7

Primer on Tumor Immunology and Cancer Immunotherapy™

Social Activity: 
Early Career Scientist Networking Reception

Workshop on Intratumoral Immunomodulation

Meet-the-Expert Lunch
Grant Writing Workshop
34th Annual Meeting
Friday, Nov. 8 34th Annual Meeting Social Activity:
Poster Reception
Saturday, Nov. 9
34th Annual Meeting Social Activities:
Award Ceremony
Poster Reception
The Checkpoints Band Party
Sunday, Nov. 10 34th Annual Meeting Hot Topic Symposium